Fig. 1 · Structure

Documents & Downloads

Carvedilol

Cat. No. A11843 CAS 72956-09-3

β2-adrenergic receptor

Carvedilol is a β1- and β2-adrenergic receptor (AR) agonist with antioxidant properties.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
α1-adrenergic receptor
β1-adrenergic receptor

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 13.01 μM Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay [PMID: 32216987]
HEK293 IC50 12 μM Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method [PMID: 21030469]
HEK293 IC50 15.9 μM Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay [PMID: 24124794]
HEK293 IC50 27 μM Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method [PMID: 21030469]
HEK293 IC50 3.4 μM Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay [PMID: 28230985]
HEK293 IC50 7.5 μM Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 92.4 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
L02 IC50 85 μM Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay 10.1039/C3MD00397C
SK-MEL-28 IC50 15.55 μM Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay [PMID: 32216987]
SK-MEL-5 IC50 13.73 μM Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay [PMID: 32216987]

10 records · Scroll to view more

Carvedilol Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Carvedilol from 2 published references. In vitro models include HEK293 wt cells stably expressing SNAP-tagged β2ARs.

Carvedilol In Vitro Studies

Carvedilol was evaluated by line scan analysis in HEK293 wt cells stably expressing SNAP-tagged β2ARs. Treatment at 10 µM for 20 min did not alter fluorescence intensity distribution, whereas ISO dampened plasma membrane fluorescence and enhanced cytoplasmic fluorescence. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Fluorescence Distribution in Receptor-Expressing Cells

Cell-based study · HEK293 wt cells stably expressing SNAP-tagged β2ARs [1]

In HEK293 wt cells stably expressing SNAP-tagged β2ARs, Carvedilol at 10 µM for 20 min did not alter fluorescence intensity distribution in line scan analysis. ISO dampened plasma membrane fluorescence and enhanced cytoplasmic fluorescence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Line scan analysisReported result 10 µM carvedilol for 20 min: Carvedilol did not alter fluorescence intensity distribution in contrast to ISO, which dampened plasma membrane but enhanced cytoplasmic fluorescence.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
20 min
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Carvedilol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Carvedilol does not promote detectable internalization of β2AR (S53); Fig. 4 legend (S314)

Line scan analysis: Line scan analysis; comparator: buffer (w/o) — Results > Carvedilol does not promote detectable internalization of β2AR (S53); Fig. 4 legend (S314)

Carvedilol In Vivo Studies

Following intraperitoneal injection, Carvedilol increased cardiac EF in WT but not NOS3-KO mice in a dose-dependent manner. The response was maximal at 100 μg/kg. [2]

Carvedilol increases cardiac EF in WT mice

Animal study · WT; mice; n = 9-12 [2]

Following intraperitoneal injection, Carvedilol increased cardiac EF in WT but not NOS3-KO mice in a dose-dependent manner. The response was maximal at 100 μg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cardiac EFReported result increased cardiac EF in WT but not NOS3-KO mice in a dose-dependent manner, which had a maximized response at 100 μg/kg[2]

Conditions shared by the study groups

Route
intraperitoneal injection
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Carvedilol 1-1,000 μg/kgbefore drug treatmentincreased cardiac EF in WT but not NOS3-KO mice in a dose-dependent manner, which had a maximized response at 100 μg/kg[2]
Carvedilol 1-1,000 μg/kg
Model: WT; mice; n = 9-12
Reported limits: Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Carvedilol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > NOS1 and NOS3 dictate spatially biased cyclic nucleotide signals in a β1AR ligand–specific manner (S143, S152, S153)

cardiac EF: cardiac EF; comparator: before drug treatment — Results > NOS1 and NOS3 dictate spatially biased cyclic nucleotide signals in a β1AR ligand–specific manner (S143)

Carvedilol 1-1,000 μg/kg · Results > NOS1 and NOS3 dictate spatially biased cyclic nucleotide signals in a β1AR ligand–specific manner (S143, S152)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 72956-09-3
Applications β2-adrenergic receptor
Formula C24H26N2O4
Molecular Weight 406.48
Synonyms Coreg; Dilatrend; BM 14190
SMILES
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 78 mg/mL (191.89 mM)
Water Insoluble
Ethanol 4 mg/mL (9.84 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Carvedilol Research References

  1. [1] Benkel T, Zimmermann M, Zeiner J, et al. How Carvedilol activates β2-adrenoceptors. Nat Commun (2022). PMID: 36402762 DOI: 10.1038/s41467-022-34765-w Source material
  2. [2] Wang Y, Zhao M, Liu X, et al. Carvedilol Activates a Myofilament Signaling Circuitry to Restore Cardiac Contractility in Heart Failure. JACC Basic Transl Sci (2024). PMID: 39297139 DOI: 10.1016/j.jacbts.2024.03.007 Source material

Added to your cart

View Cart Checkout
Loading...